EUVIMEDEUVIMED entdecken
Crossref

Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients

Jiayue Liu, Xiaoyi Guo, Li Wen, Lixin Wang, Futao Liu, Guohong Song, Hua Zhu, Nina Zhou, Zhi Yang

European Journal of Nuclear Medicine and Molecular Imaging · 2023-07 · 50 (9) · 2775-2786

DOI: 10.1007/s00259-023-06232-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 24.04.2023. Verfasst von Jiayue Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radio…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Breast Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Capital's Funds for Health Improvement and Research, Beijing Hospitals Authority Deng feng Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: A novel HER2 affibody-based molecular probe, [18F]AlF-RESCA-HER2-BCH, was developed for reducing renal uptake, evaluated, and compared with [18F]AlF-NOTA-HER2-BCH. METHODS: In preclinical studies, micro-PET/CT was performed using HER2-positive gastric cancer patient-derived xenografts (PDX) model at 0.5-1 (dynamic), 2, 4, and 6 h post-injection. For blocking experiment, 0.5 mg cold affibody was co-injected with probes. Biodistribution were performed on HER2-positive PDX models at 2 h post-injection. For clinical study, PET/CT images were acquired at 2 h and 4 h after injection of 231.29 ± 17.77 MBq [18F]AlF-NOTA-HER2-BCH or [18F]AlF-RESCA-HER2-BCH in five breast cancer patients (4 HER2-positive and 1 HER2-low). Standardized uptake values (SUVs) were measured in tumors and source-organs for semi-quantitative analysis. The OLINDA/EXM software (version 1.2) was used to calculate the radiation doses. RESULTS: [18F]AlF-NOTA-HER2-BCH and [18F]AlF-RESCA-HER2-BCH were stably labeled with [18F]F, with high binding specificity and affinity to HER2. Micro-PET/CT of both tracers could clearly visualize HER2-positive PDX tumors with high uptake of 16.24 ± 1.74% ID/g and 14.39 ± 2.45% ID/g at 2 h post-injection. The renal accumulation of [18F]AlF-RESCA-HER2-BCH was significantly lower than that of [18F]AlF-NOTA-HER2-BCH (5.16 ± 0.22% ID/g vs. 158.73 ± 5.44% ID/g at 2 h, p < 0.0001). In the clinical study, both [18F]AlF-NOTA-HER2-BCH and [18F]AlF-RESCA-HER2-BCH demonstrated favorable tumor targeting and image contrast. [18F]AlF-RESCA-HER2-BCH showed a higher SUVmax in both primary tumor and metastases, and a significantly higher target-to-nontarget ratio in metastases than [18F]AlF-NOTA-HER2-BCH. Moreover, [18F]AlF-RESCA-HER2-BCH had lower renal accumulation (43.56 ± 7.88 vs. 79.81 ± 3.81 at 2 h, p < 0.0001; 33.23 ± 6.89 vs. 78.63 ± 4.00 at 4 h, p < 0.0001) as well as a significantly lower renal absorbed dose than [18F]AlF-NOTA-HER2-BCH (0.4450 ± 0.1117 mGy/MBq vs. 0.8030 ± 0.1604 mGy/MBq, p < 0.01). CONCLUSIONS: [18F]AlF-RESCA-HER2-BCH tended to provide better image contrast than [18F]AlF-NOTA-HER2-BCH with a higher target-to-nontarget ratio in detection of metastases. Notably, [18F]AlF-RESCA-HER2-BCH had lower renal accumulation than [18F]AlF-NOTA-HER2-BCH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyBreast NeoplasmsMiceHumansAnimalsFemaleTissue DistributionCell Line, TumorFluorine RadioisotopesHeterocyclic Compounds, 1-RingPositron-Emission Tomography

Stichwörter der Autor:innen

Fluorine-18 labelingHER2 affibodyPET/CT[18F]AlF-NOTA-HER2-BCH[18F]AlF-RESCA-HER2-BCH

Substanzen

1,4,7-triazacyclononane-N,N',N''-triacetic acidFluorine RadioisotopesHeterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department…
  • Guizhou University School of Medicine, Guizhou University, Guiyang, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Biochemistry and Molecular Biology, Peking University Cancer Hospital & Institute, Beijing, China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China.

Förderung

  • National Natural Science Foundation of China
  • Capital's Funds for Health Improvement and Research
  • Beijing Hospitals Authority Deng feng Project
  • The Pilot Project (4 th Round) to Reform Public Development of Beijing Municipal Medical Research Institute
  • Science Foundation of Peking University Cancer Hospital
  • Capital’s Funds for Health Improvement and Research

Zitieren

APA

Liu, J., Guo, X., Wen, L., Wang, L., Liu, F., Song, G., Zhu, H., Zhou, N., & Yang, Z. (2023). Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 50(9), 2775-2786. https://doi.org/10.1007/s00259-023-06232-1

Vancouver

Liu J, Guo X, Wen L, Wang L, Liu F, Song G, et al. Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging. 2023;50(9):2775-2786. doi:10.1007/s00259-023-06232-1

BibTeX
@article{Liu2023,
  author = {Liu, Jiayue and Guo, Xiaoyi and Wen, Li and Wang, Lixin and Liu, Futao and Song, Guohong and Zhu, Hua and Zhou, Nina and Yang, Zhi},
  title = {Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2023},
  volume = {50},
  number = {9},
  pages = {2775--2786},
  doi = {10.1007/s00259-023-06232-1}
}
Kostenlos starten →